# PK Study of Dapagliflozin in Pediatric Subjects With T2DM

> **NCT01525238** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 53 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT01525238
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-01
- **Primary completion:** 2014-09-01
- **Final completion:** 2014-09-01
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2017-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01525238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01525238, "PK Study of Dapagliflozin in Pediatric Subjects With T2DM". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01525238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*